Long-Term Response to Galantamine in Relation to Short-Term Efficacy Data: Pooled Analysis in Patients with Mild to Moderate Alzheimer's Disease

By  

Current Alzheimer Research, Vol. 8, Iss. 2, 2011-03 ,pp. : 175-186

Bentham Science Publishers

Access to resources Recommend Favorite

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

By Ott Brian   Blake Lesley   Kagan Ethel   Resnick Malca  

Journal of Neurology, Vol. 254, Iss. 3, 2007-03 ,pp. : 351-358

Springer Publishing Company

Access to resources Recommend Favorite

Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer’s Disease: A Phase 2, Open-Label Extension Study

By  

Current Alzheimer Research, Vol. 15, Iss. 13, 2018-12 ,pp. : 1231-1243

Bentham Science Publishers

Access to resources Recommend Favorite

Awareness of cognitive deficits and clinical competence in mild to moderate Alzheimer’s disease: their relevance in clinical practice

By Gambina G.   Bonazzi A.   Valbusa V.   Condoleo M.   Bortolami O.   Broggio E.   Sala F.   Moretto G.   Moro V.  

Neurological Sciences, Vol. 35, Iss. 3, 2014-03 ,pp. : 385-390

Springer Publishing Company

Access to resources Recommend Favorite

Prevalence of Frailty in Mild to Moderate Alzheimer's Disease: A Systematic Review and Meta-analysis

By  

Current Alzheimer Research, Vol. 14, Iss. 12, 2017-10 ,pp. : 1256-1263

Bentham Science Publishers

Access to resources Recommend Favorite